Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

March 11, 2008 10:44 ET

Novadaq to Present at Cowen Healthcare Conference

TORONTO, ONTARIO--(Marketwire - March 11, 2008) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time medical imaging
systems and image guided therapies for the operating room, today announced that
Dr. Arun Menawat, President & CEO of Novadaq, will present the corporate story,
technology and highlights, including an update on commercial development and the
pipeline, at the Cowen & Co. Healthcare Conference. The conference runs Monday,
March 17 through Thursday, March 20 at the Boston Marriott Copley Hotel.

Dr. Menawat's presentation is at 1:40 p.m. ET on Tuesday, March 18 and
will be webcast live from Novadaq's website at www.novadaq.com.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging systems and real-time image guided therapies for use in the operating
room. Novadaq's proprietary ICG imaging systems can be used to visualize blood
vessels, nerves and the lymphatic system during a variety of surgical
procedures. Novadaq's SPY® Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of heart bypass surgery. The SPY System
is expandable to include upgrade kits for use during other surgeries such as
other cardiovascular, plastic, reconstructive and organ transplant surgery
allowing surgeons to evaluate blood flow and tissue and organ perfusion. In
addition, SPY is ideal for use during urological procedures enabling surgeons
to visualize vessels, tumors, the lymphatic system and potentially nerve
bundles. Novadaq's OPTTX® System is aimed at the diagnosis, evaluation and
treatment of wet Age-related Macular Degeneration (AMD) by using the same core
imaging technology that is used in the SPY Imaging System. Novadaq also offers
the FDA approved PINPOINT™ endoscopic system for visualizing native tissue
fluorescence which allows surgeons to differentiate between healthy and
cancerous tissue in the lung during thoracic surgery. Novadaq is also the
exclusive United States distributor of PLC Medical's CO2 HEART LASER™
System for TMR (Trans-Myocardial Revascularization). For more information,
please visit the company's website at www.novadaq.com.

Forward looking Statements

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information: visit our website at www.novadaq.com.

Contact Information